Via practica 3/2021

Coagulopathy associated with COVID-19 infection Safe and effective thromboprophylaxis is essential for patient survival

The pandemic of COVID-19 has become an urgent problem in every country. In the case of infection with this virus, many experts have reported the presence of coagulopathy associated with massive intravascular thrombus formation, which is similar as disseminated intravascular coagulation (DIC). Regular coagulation tests and active procoagulant management are useful for the management of severe cases. The clinical manifestation of coagulopathy is associated with organ dysfunction caused by microthrombotic in organs. Haemorrhagic events are uncommon. The most important haemostatic biomarker is the increase in D-dimer and fibrin / fibrinogen degradation products. In addition to activating coagulation with high plasma D-dimer, platelet depletion and thrombocytopenia, together with unfavourable prognostic markers and determinants of high mortality. Endothelial cell damage is an important feature of the pathogenesis of respiratory syndrome COVID-19. A thrombosis prevention strategy is essential for improving organ function and patient survival.

Keywords: COVID-19, coagulopathy, D-dimer, anticoagulant strategy, heparin